Phase I single-ascending dose (SAD) trial of ARI 3037MO

Trial Profile

Phase I single-ascending dose (SAD) trial of ARI 3037MO

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2012

At a glance

  • Drugs ARI 3037MO (Primary)
  • Indications Dyslipidaemias
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms SAD
  • Most Recent Events

    • 07 Nov 2012 Status changed from planning to completed, based on results reported in an Arisaph Pharmaceuticals media release.
    • 23 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top